Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
Hospital price transparency rules produce measurable cost reductions only for self-pay patients seeking elective procedures while insured patients show no behavioral change because insurance insulates them from marginal cost
Multiple 2025 studies show hospital price transparency compliance remains poor (55% of hospitals had not posted readable price files 6 months after rule took effect) and market impact is highly selective. Pan & Yaraghi's SAGE 2025 analysis found that transparency 'does NOT broadly reduce hospital ch
GLP-1 weight-loss coverage is declining at the employer and health system level despite rising utilization creating a widening access gap driven by cost pressures that exceed VBC cost management capacity
Covered individuals enrolled in employer-sponsored GLP-1 weight-loss coverage declined from 3.6 million in 2024 to 2.8 million in 2026, a 22% decrease, even as overall GLP-1 utilization continues rising. Major health systems have discontinued coverage entirely: Allina Health, RWJBarnabas Health, Asc
MHPAEA enforcement closes coverage gaps but not access gaps because payers differentially treat mental health versus medical reimbursement rates
The 2025 MHPAEA Report to Congress documents a specific structural mechanism explaining why mental health parity enforcement improves coverage mandates without closing access gaps. EBSA found multiple instances where plan sponsors and issuers 'actively increased reimbursement rates for certain M/S [
MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
The 2024 MSSP results provide the strongest empirical evidence that value-based care's structural fix thesis works at scale. ACOs generated $2.48B in net Medicare savings (after shared savings payments) for the eighth consecutive year, with per capita net savings increasing from $207 in 2023 to $241
Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
Eli Lilly launched Employer Connect on March 5, 2026, offering Zepbound at $449/dose directly to employers — a 55-60% discount versus $1,000+ retail pricing. The program operates through 15+ program administrator partnerships including GoodRx, Teladoc, Calibrate, Form Health, and Waltz, completely b
GLP-1 behavioral support mandates tripled in one year (10% to 34%) signaling structural shift from drug-only formulary to managed-access operating systems
PHTI's December 2025 employer survey found that 34% of firms covering GLP-1s now require dietitian, case management, therapy, or lifestyle participation as a coverage condition, up from 10% the prior year—a 3.4x increase in 12 months. This is not incremental adoption but structural acceleration. Thr
GLP-1 behavioral support market stratifies by physical integration level with atoms-to-bits companies achieving profitability while behavioral-only companies fail
The GLP-1 behavioral support market has stratified into four distinct tiers with dramatically different commercial outcomes as of April 2026. Tier 1 (access-first, no behavioral/physical integration) faces FDA enforcement and legal action — exemplified by a 2-person AI telehealth startup with $1.8B
GLP-1 managed-access infrastructure layer creates a distinct platform opportunity separate from behavioral coaching
PHTI identifies five infrastructure components required for managed GLP-1 access: (1) utilization management infrastructure, (2) outcomes-based contracting frameworks, (3) indication-specific cardiometabolic programs (CVD, OSA, MASH, perimenopause, prediabetes), (4) adherence, tapering, and disconti
LLM behavioral coaching matches human coach message quality after refinement but fails to achieve clinical equivalence due to privacy, bias, and safety concerns
Huang et al. (2025) conducted the first peer-reviewed direct comparison of LLM versus human-generated coaching messages in behavioral weight loss programs. Initial LLM messages were rated less helpful than human coaches (66% vs 82% scoring ≥3 on helpfulness). However, after revision and refinement,
GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
Traditional formulary yes/no structure cannot accommodate GLP-1 economics at scale. The eligible commercially insured population is 36.2 million adults, with recurring costs of $1,000-$1,200+/month and expanding indications (obesity, T2D, cardiovascular risk 2024, MASH F2-F3 fibrosis 2025, sleep apn
CGM-integrated GLP-1 behavioral support achieves fundamentally different unit economics than coaching-only models, enabling profitability at lower revenue scales
Omada Health achieved profitability ($5.16M net income) at $260M annual revenue in 2025 while integrating physical monitoring devices (Abbott FreeStyle Libre CGMs) into its GLP-1 behavioral support program. This stands in stark contrast to WeightWatchers, which filed for bankruptcy at comparable rev
AI displacement of cognitive workers creates a second wave of deaths of despair that extends the manufacturing displacement mechanism to professional classes
The paper argues that generative AI creates a structurally novel displacement mechanism compared to previous automation waves. Unlike manufacturing automation that targeted routine manual tasks, AI targets cognitive work—approximately 60% of US job tasks face medium-to-high AI replacement risk withi
Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
Truveta's real-world analysis found that patients receiving GLP-1 therapy from endocrinologists and obesity specialists demonstrate higher 12-week completion rates compared to those treated by primary care providers. This specialist advantage persists after controlling for patient-level factors incl
GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
Truveta's analysis of real-world GLP-1 discontinuation patterns found that patients with a history of psychiatric medication use are 12 percent more likely to discontinue GLP-1 therapy compared to those without psychiatric history. This creates a compounding access-adherence trap: patients with co-o
Clinical AI human-first reasoning prevents never-skilling through pedagogical sequencing where trainees generate differential diagnoses before AI consultation
The resident supervision study (PMC 2026) identifies a specific pedagogical intervention to prevent never-skilling: residents must generate their own differential diagnosis before consulting AI. This is not abstract guidance about 'AI should supplement not replace' but an operational protocol with e
Physician consolidation with hospital systems raises commercial insurance prices 16-21% for specialty procedures while producing no consistent quality improvement
The GAO's systematic review of published literature found that hospital-affiliated specialists negotiated 16.3% higher prices for cardiology procedures and 20.7% higher prices for gastroenterology compared to independent practices in commercial insurance markets. Private equity-affiliated specialist
US avoidable mortality increased in all 50 states from 2009-2019 while declining in most high-income countries, with health spending structurally decoupled from outcomes within the US but not in peer nations
This study provides definitive evidence of a structural divergence in health system performance. From 2009-2019, avoidable mortality increased by a median 29.0 per 100,000 across US states (total average increase 32.5), while EU countries decreased by 25.2 and OECD countries by 22.8. The directional
GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk
A genome-wide association study of 27,885 individuals using semaglutide or tirzepatide identified genetic variants that explain significant portions of treatment response variability. A missense variant in GLP1R was associated with an additional -0.76 kg weight loss per copy of the effect allele, co
Private equity firms drove 65% of physician practice acquisitions from 2019-2023 while owning only 7% of practices, indicating structural transformation is accelerating faster than ownership share suggests
The GAO report documents that private equity firms were responsible for 65% of all physician practice acquisitions from 2019-2023, yet PE ownership represents only 6.5-7% of physicians nationally as of 2024 (up from ~5% in 2022). This creates a striking velocity-to-ownership ratio: PE is acquiring p
WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions
The WHO guideline represents a critical policy signal: despite moderate-certainty evidence of efficacy from trials of liraglutide, semaglutide, and tirzepatide, the organization issued a conditional rather than strong recommendation. The conditionality is explicitly attributed to non-clinical factor
AI-induced upskilling inhibition prevents skill acquisition in trainees through routine case reduction creating a distinct never-skilling pathway
This mixed-method review introduces 'upskilling inhibition' as a distinct concept from deskilling. While deskilling affects experienced practitioners who lose skills through disuse, upskilling inhibition affects trainees who never acquire skills in the first place. The mechanism: AI systems handle r
Moral deskilling from AI erodes ethical judgment through repeated cognitive offloading creating a safety risk distinct from diagnostic accuracy
The paper introduces 'moral deskilling' as a distinct category of AI-induced harm separate from diagnostic deskilling. While diagnostic deskilling affects clinical accuracy (forming differential diagnoses, physical examination skills), moral deskilling affects ethical judgment capacity. The mechanis
Clinical AI deskilling is a generational risk affecting future trainees rather than current practitioners because experienced clinicians retain pre-AI skill foundations while new trainees face never-skilling in AI-saturated environments
The ARISE 2026 report synthesizing 2025 clinical AI research documents a critical temporal distinction in deskilling risk. Current practicing clinicians report NO measurable deskilling from AI applications, which the report attributes to their pre-AI clinical training providing a skill foundation th
Clinical AI creates moral deskilling through ethical judgment erosion from routine AI acceptance leaving clinicians unprepared to recognize value conflicts
This review introduces 'moral deskilling' as a distinct form of AI-induced competency loss separate from cognitive deskilling. The mechanism: repeated acceptance of AI recommendations creates habituation that reduces ethical sensitivity and moral judgment capacity. Clinicians become less prepared to
Clinical AI upskilling requires deliberate educational mechanisms and workflow design rather than occurring automatically from AI exposure
The ARISE 2026 report challenges the assumption that AI assistance automatically produces upskilling through time liberation. While the report confirms that 'current AI applications function primarily as assistants rather than autonomous agents, offering an opportunity for upskilling by liberating c
Page 5 of 13